Lake Street raised the firm’s price target on Insight Molecular Diagnostics (IMDX) to $12 from $8 and keeps a Buy rating on the shares. With Insight having completed a $26M offering last week, cash on hand is now secured beyond a potential approval later this year, notes the analyst, who expects an FDA submission for GraftAssureDx in the coming weeks to be a catalyst for shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMDX:
- Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D
- Insight Molecular Diagnostics Provides Updated Investor Presentation Materials
- Insight Molecular Diagnostics prices 4.53M shares at $5.75 in direct offering
- Insight ‘congratulated’ STAR working group on organ health testing paper
- Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs